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INTRODUCTION 
So any disorder that leads to disharmony 
and therefore consent to sexual relations, 
may be associated with sexual 
dysfunction.
1,2
 Sexual dysfunction 
influences the life quality of millions of men 
and their partners in the world and most of 
them prefer to suffer in silence.
3
 Sexual 
issues in marriage are primarily important 
and compatibility in sex is an important 
factor affecting happiness.
4
 Optimally, 
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ABSTRACT 
Background and aims: Sexual dysfunction is a common complaint among drug abusers 
in the treatment with Methadone and Buprenorphine. The aim of this study was to assess 
sexual dysfunction in patients undergoing Methadone or Buprenorphine for maintenance 
therapy. 
Methods: This research was a cross-sectional study. A 3-parts questionnaire 
(demographic questions, international index of erectile function questionnaire (IIEF) and 
Beck Depression Inventory (BDI-II)) was used for data collection. 
Results: Overall, 3.5% reported no Erectile Dysfunction (ED), 79.9 % reported mild to 
moderate ED, and 10% reported severe ED. There were no statistical differences in the 
components of the IIEF questionnaire between Methadone maintenance treatment (MMT) 
and Buprenorphine maintenance treatment (BMT) group. Statistical analysis show that 
depressed subjects has a higher sexual dysfunction (r= -0.435, P<0.001). The results showed 
no significant relation between drug dose and sexual function (r= 0.031, P= 780). 
Conclusions: Based on our findings, sexual dysfunction was relatively high among 
males who received MMT and BMT and the disorder was more prevalent in depressed 
people. As the results, the problem needs more attention and should be offered the right 
solution to solve it. 
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satisfying the sexual desires play a pivotal 
role in the development of the human 
personality, individual and social health, and 
achieving peace and comfort.
5
 In most cases, 
sexual dysfunction and lack of sexual 
satisfaction will lead to the collapse of the 
family foundation.
6
 Sexual dysfunction in 
men is the inability to achieve sexual 
satisfaction in a sexual relationship, and may 
be due to insufficient erections, difficulty 
poured semen into prostatic urethra or 
ejaculatory difficulty.
7
 Many patients who 
suffer from erectile dysfunction aren’t able 
to share this problem with their consultants 
and on the other hand, many clinical care 
providers and counselors feels discomfort 
and embarrassment when dealing with 
patients having sexual problems.
3
 Most 
common sexual dysfunction in 18 to 59 
years old men, includes: Premature 
ejaculation, loss of libido, anxiety about sex 
and  not to enjoy sexual contact.
8
 Today, the 
pharmaceutical composition of drug 
maintenance therapy (particularly 
methadone and buprenorphine) as one of the 
most common and most valuable therapy to 
reduce the risk of drug using.
9
 In the United 
States of America, over 150,000 drug-
dependent patients are treated with 
methadone.
10
 Erectile dysfunction is a 
common side effect of heroin abusers and 
the prevalence in patients undergoing 
maintenance treatment between 7 to 33% 
have been reported.
9,11-13
 Sexual dysfunction 
is one of the biggest obstacles to the 
continuation of conservative therapy, 
especially in patients with increased 
duration of treatment, and high dose.
14
 
Although sexual dysfunction, a 
common complaint among drug abusers in 
methadone maintenance treatment is 
beginning in the world, few studies exist 
regarding sexual function of addicts in Iran 
and the world. Bliesener et al. studied a 
group of heroin abusers, indicating the 
significant prevalence of the disorder among 
patients starting treatment. A research in 
which 201 male drug abuser undergoing 
methadone maintenance treatment were 
randomly assigned to 7 clinics, found that 
24% of the patients had disorders of  
mild-moderate sex and 18% of them 
suffered from severe disorders of sex.
15
 
Similar studies regarding the prevalence of 
sexual dysfunction in drug users occurred in 
which the researchers found that patients 
had severe sexual dysfunction, especially 
erectile dysfunction.
16
 Hanbury et al, in the 
study of 50 patients treated with methadone 
maintenance found that 33% of the 
participants have suffered from serious 
impairment of sexual function.
17
 Another 
study in Kermanshah on 177 opioid 
dependent patients indicates the presence of 
significant sexual dysfunction in 70% of 
patients.
18
 
Given that sexual dysfunction is a 
serious problem in patients undergoing 
methadone and buprenorphine maintenance 
treatment, determining the extent of the 
disorder is necessary. The present study 
aims to assess the sexual dysfunction in 
patients undergoing methadone and 
buprenorphine maintenance therapy in 
Tehran (Rahe Roshan and Farabi hospital 
addiction treatment center). Because of 
socio-cultural limitations in Iran, our study 
focused on evaluating sexual dysfunctions in 
married men. 
 
METHODS 
The cross-sectional study was 
conducted to evaluate the sexual dysfunction 
on married men who referred to addiction 
treatment centers, substance abuse and 
dependence in Tehran in 2014. Using 
similar studies, the sample size of the study 
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was determined at 110. Finally, 85 people 
that completed the questionnaires entered in 
the data analysis (N= 52 in Methadone and 
N= 33 in Buprenorphine). 
The inclusion criteria of the study was 
being married male, having at least 18 years 
old, a history of drug dependence, and 
written informed consent to participate in 
the study. Participants who had a chronic 
disease and psychological disorders 
excluded from the study. 
A3-parts Questionnaire (demographic 
questions, international index of erectile 
function questionnaire (IIEF) and Beck 
Depression Inventory (BDI-II)) was used for 
data collection. IIEF has 15 questions, 
including: Erectile Function (6 questions), 
Orgasmic Function (2 questions), Sexual 
Desire (2 questions), Intercourse Satisfaction 
(3 questions) and Overall Satisfaction  
(2 questions). The maximum score is 75 that 
represent the best sexual function. Based on 
Erectile Function score, the participants 
categorized as follows; No erectile 
dysfunction (score 26-30), Mild erectile 
dysfunction (score 22-25), Mild to moderate 
erectile dysfunction (score 17-21), Moderate 
erectile dysfunction (score 11-16), and 
Severe erectile dysfunction (score 6-10).
19
  
The BDI-II contains 21 questions, each 
answer being scored on a scale value of 0-3. 
The cutoffs use differs from the original;  
0-13: minimal depression, 14-19: mild 
depression, 20-28: moderate depression, and 
29-63: severe depression.
20
 
Descriptive statistics were presented by 
mean and standard deviation for quantitative 
data, and frequency for qualitative data.  
The distribution of data was checked by 
Kolmogorov-Smirnov test. For investigating 
the relations between variables, T-test,  
Chi-square and Pearson correlation coefficient 
were used. The significance level was 
considered in 0.05. All data analysis was done 
using SPSS. 
 
RESULTS 
In this study, 110 addicts were studied 
that information about the 85 of them was 
completed. The response rate in Methadone 
group was 74% and in Buprenorphine group 
was 82.5%. Basic characteristics of patients 
are presented in Table 1. 
 
Table 1: Basic characteristics of patients 
Characteristics N0. % Mean ± SD 
Age   
33.7 ± 4.6 Education ≤12 years 76(71.8) 
>12 years 24(28.2) 
Economic Status Weak 22(25.9) 
Moderate 45(52.9) 
Good 18(21.2) 
History of sexual disorder Yes 9(10.6) 
No 76(89.4) 
Employment Employed 79(92.9) 
Unemployed 6(7.1) 
 
Table 2 shows the distributions of the 
erectile function scores for patients in 
methadone and buprenorphine maintenance 
treatment. Overall, 3.5% reported no ED, 
79.9 % reported mild to moderate ED, and 
10.6% reported severe ED. The median 
score was 17, and the mean ± SD was 
17.07±2.6. 
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Table 2: Score of the erectile function of patients in methadone and buprenorphine treatment 
Erectile dysfunction Methadone patients, no. (%) Buprenorphine patients, no. (%) Total, no. (%) P 
Severe (score 6-10) 5 (9.6) 4(12.1) 9 (10.6) 0.909 
Moderate (score 11-16) 17(32.7) 10(30.3) 27(31.8) 
Mild to moderate (score 17-21) 22(42.3) 12(36.4) 34 (40) 
Mild (score 22-25) 6(11.5) 6(18.2) 12(14.1) 
No erectile dysfunction (score 26-30) 2(3.8) 1(3.0) 3(3.5) 
 
The mean score of overall Satisfaction 
was 5.6±1.6 (5.57 in MMT and 5.72 in 
BMT). Orgasmic Function was 5.54±2.01 
(5.34 in MMT and 5.84 in BMT). Sexual 
Desire was 5.63±1.87 (5.59 in MMT and 
5.69 in BMT). Intercourse Satisfaction was 
8.56±2.84 (8.67 in MMT and 8.39 in 
BMT). Erectile function was 17.07±4.5 
(17.09 in MMT and 17.03 in BMT). Total 
score was 42.4±11.7 (42.2 in MMT and 
42.7 in BMT). There were no statistical 
differences in the components of the IIEF 
questionnaire between MMT and BMT 
group. The results of the t-test analysis 
between the two groups are represented in 
Table 3. 
 
Table 3: The result of t-test analyze between methadone and buprenorphine treatment 
Variable MMT (Mean) BMT (Mean) P Mean difference 95% CI for difference 
Erectile Function 17.09  17.03 0.956 -0.05 -1.96, 2.07 
Orgasmic Function 53.4 5.84 0.265 -0.50 -1.39, 0.38 
Sexual Desire 5.59 5.69 0.811 -0.10 -0.93, 0.73 
Intercourse Satisfaction 8.67 8.39 0.662 0.27 -0.98, 1.54 
Overall Satisfaction 5.57 5.72 0.689 -0.15 -0.89, 0.59 
Total score 42.2 42.7 0.874 -0.41 -5.64, 4.80 
 
Our results showed that 18.8 % of 
patients have moderate or severe 
depression. Comparison of depression 
status in two groups shown in Table 4. 
Statistical analysis shows that a significant 
indirect relation between depression and 
sexual function (r= -0.435, P<0.001). There 
was no significant relation between drug 
dose and depression (r= -0.001, P= 0.952). 
Also, the results showed no significant 
relation between drug dose and sexual 
function (r= 0.031, P= 780). 
 
Table 4: Comparison of depression status in two groups 
Levels of Depression MMT, No. (%) BMT, No. (%) Total, No. (%) P 
Normal 23(44.2) 20(60.6) 43(50.6) 0.57 
Mild mood disturbance 13(25) 7(21.2) 20(23.5) 
Borderline clinical depression 4(7.7) 2(6.1) 6(7.1) 
Moderate depression 7(13.5) 2(6.1) 9(10.6) 
Severe depression 3(5.8) 1(3) 4(4.7) 
Extreme depression 2(3.8) 1(3) 3(3.5) 
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DISCUSSION 
In the present study, 10 % of the 
patients reported severe ED and about one 
third reported moderate ED. The percentage 
of patients reported ED is moderately lower 
than the percentages reported ED in 
previous studies and higher than the general 
population study of 2000 Italian males aged 
18-39 years in which only 2% reported 
ED.
11,13,21-23
 In our project we see no 
statistical differences in any type of sexual 
dysfunction between MMT and BMT group. 
Whereas, some studies demonstrated that 
patients in the methadone group had a 
higher rate of sexual dysfunction in 
comparison with the buprenorphine.
11,13,24
 
The results of a meta-analysis shows that 
sexual dysfunction was significantly higher 
combined odds ratio in the methadone 
group.
12
 Our justification for the differences 
is that the differences in the characteristics 
of the study population. Also, the difference 
in results may be due to socio-economic 
differences across the communities.
25,26
 The 
prevalence of moderate to severe depression 
in the patients in our study was 18.8%, while 
in the study of erectile dysfunction in male 
heroin users, receiving methadone and 
buprenorphine. It was 34 % and 38 % in 
another study.
11,13
 Our results show that that 
depressed subjects had more sexual 
dysfunction that this finding was similar to 
previous studies.
11-13,27
 We sought no 
significant association between drug dose 
and sexual function status while, in the study 
among 31 male and 17 female former 
addicts in methadone maintenance daily 
methadone dose (mg/kg) correlated 
significantly with frequency of sexual 
contacts and ejaculation.
28
 
Sexual dysfunction and depression 
status were investigated in this study. 
Methadone and Buprenorphine had no 
different influence on sexual function but 
depressed patients had a greater problem in 
this disorder. 
CONCLUSION 
Based on our findings, sexual 
dysfunction was relatively high among 
males who received MMT and BMT and 
the disorder was more prevalent in 
depressed people. As the results, the 
problem needs more attention and should 
be offered the right solution to solve it. For 
this reason, depression can be a good 
indicator for screening people at risk to 
sexual dysfunction. However, further 
studies are necessary to make correct 
decisions about this. 
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